Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

Summary

This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.

Timeline

Start

2017-12-15

Primary completion

2019-08-02

Completion

2019-10-17

Outcome

Missed primary endpoint

registry analysis (superiority test); Secukinumab vs Placebo; p = 0.875; Mean Difference (Final Values) -0.77 (90% CI -8.84 to 7.30); LS mean NCT03344640 ↗

Publications

• Millar NL, McInnes IB, Kolbinger F, Raulf F, Akbar M, Li Y, Beckmann N, Accart N, Leupin O, Calonder C, Schieker M, Kneissel M, Bruns C, Siegel RM, Weber E. Targeting the IL-17A pathway for therapy in early-stage tendinopathy. RMD Open. 2025 Feb 23;11(1):e004729. doi: 10.1136/rmdopen-2024-004729.

Drugs

Indications